08:16 AM EDT, 07/11/2024 (MT Newswires) -- Akebia Therapeutics ( AKBA ) said Thursday that it has regained full rights to commercialize Vafseo tablets in the US after agreeing to terminate a license agreement with CSL Vifor.

Akebia said it is now allowed to deal directly with all dialysis organizations effective immediately.

Akebia said CSL Vifor is entitled to quarterly tiered royalty payments of a high single-digit percentage on annual net sales under $450 million and a mid-single-digit percentage for sales above that amount.

Akebia said that it has the option to buy down the royalty agreement starting July 1, 2027 with a one-time payment to CSL Vifor, reducing royalty payments to a mid-single digit percentage of Akebia's annual net sales of Vafseo up to $450 million and eliminating royalty payments on annual net sales exceeding $450 million.

Akebia set the wholesale cost of Vafseo in the US at $1,278 for a 30-day supply.

Shares of Akebia were up 3.7% in recent Thursday premarket activity.

Price: 1.1200, Change: +0.04, Percent Change: +3.70